Medical Condition News

RSS

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers (H. pylori bacteria).

2 Jun 2015

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.

2 Jun 2015

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

People with achromatopsia, an inherited eye disorder, see the world literally in black and white. Worse yet, their extreme sensitivity to light makes them nearly blind in bright sunlight. Now, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute at UC San Diego Health System have identified a previously unknown gene mutation that underlies this disorder.

2 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.

2 Jun 2015

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys AG today announced updated clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies.

2 Jun 2015

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Genticel, a French biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces today positive preclinical in vivo proof of concept results of GTL002, its multivalent HPV therapeutic vaccine candidate based on the Company’s versatile Vaxiclase platform.

2 Jun 2015

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

Mount Sinai Health System faculty will be presenting research updates on a lymphoma vaccine clinical trial, the best dosing for a drug against metastatic cancer, and new treatment strategies in relapsed multiple myeloma at the American Society of Clinical Oncology annual meeting, May 29 - June 2, 2015, in Chicago.

2 Jun 2015

SIRFLOX study promises better and earlier treatment option for liver cancer patients

The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2015

ERC Advanced Grants awarded to seven ETH researchers

Seven ETH Zurich professors have applied successfully for an ERC Advanced Grant, which is worth about CHF 2.5 million. Two of the seven received the coveted award for the second time.

1 Jun 2015

Academics from University of Zurich selected to receive EU's most prestigious research grant

Two male academics and one female academic from the University of Zurich have been selected to receive the EU's most prestigious research grant. Each will receive between 2.5 and 2.9 million Euro to support innovative research projects over the next five years.

1 Jun 2015

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Cantex Pharmaceuticals, a clinical stage biopharmaceutical company developing medications that block critical mechanisms by which cancer spreads and resists treatment, today announced Tibor Kovacsovics, M.D., Medical Director for the Inpatient Service of the Division of Hematology and Hematologic Malignancies and Director of Hematologic Malignancy Clinical Research at Huntsman Cancer Institute presented a poster related to Cantex's lead compound, CX-01, at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO).

1 Jun 2015

Modified poliovirus therapy for glioblastoma works best at a low dosage

A modified poliovirus therapy that is showing promising results for patients with glioblastoma brain tumors works best at a low dosage, according to the research team at Duke's Preston Robert Tisch Brain Tumor Center where the investigational therapy is being pioneered.

1 Jun 2015

Contaminant particles emitted by vehicles have negative repercussions in children with respiratory illnesses

Particles of less than 2.5 microns emitted by vehicles have negative repercussions for bronchiolitis, pneumonia, asthma and bronchitis in children.

1 Jun 2015

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

The National Psoriasis Foundation received a second-year of funding from the Patient-Centered Outcomes Research Institute (PCORI) for its patient-driven, online research community.

1 Jun 2015

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

SI-BONE, Inc., a medical device company that pioneered the use of the iFuse Implant System®, a minimally invasive surgical (MIS) device indicated for fusion for certain disorders of the sacroiliac (SI) joint, announced that the North American Spine Society (NASS) has issued their formal coverage recommendation for MIS SI joint fusion titled "Percutaneous Sacroiliac Joint Fusion, Defining Appropriate Coverage Positions."

1 Jun 2015

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

Funding from the Mark Cuban Foundation, run by the well-known owner of the Dallas Mavericks, will allow University of Michigan scientists and physicians to study how human growth hormone may aid recovery from an ACL tear - one of the most frequent, traumatic and dreaded knee injuries among athletes.

1 Jun 2015

ACA urges NINDS to include recommendations for use of conservative forms of pain management

The American Chiropractic Association (ACA), in recent comments submitted to the National Institute of Neurological Disorders and Stroke (NINDS) Office of Pain Policy on the draft National Pain Strategy, strongly urges the agency to include recommendations encouraging patients and health care providers to first exhaust conservative forms of pain management, when appropriate.

1 Jun 2015

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer.

1 Jun 2015

Medical Condition News

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Chronic exposure to bacteria may lead to development of Type 2 diabetes

Adaptimmune presents clinical results of NY-ESO TCR therapeutic candidate at ASCO 2015

Previously unknown gene mutation linked to inherited eye disorder, achromatopsia

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Combination of cobimetinib and vemurafenib can halt progression of metastatic melanoma for one year

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

Genticel announces positive results of new multivalent HPV therapeutic vaccine based on Vaxiclase platform

Mount Sinai Health System researchers present updates on cancer vaccine clinical trials at ASCO 2015

SIRFLOX study promises better and earlier treatment option for liver cancer patients

ERC Advanced Grants awarded to seven ETH researchers

Academics from University of Zurich selected to receive EU's most prestigious research grant

Poster related to Cantex's lead compound CX-01 presented at ASCO 2015

Modified poliovirus therapy for glioblastoma works best at a low dosage

Contaminant particles emitted by vehicles have negative repercussions in children with respiratory illnesses

National Psoriasis Foundation’s online research community receives second-year of funding from PCORI

North American Spine Society issues formal coverage recommendation for MIS SI joint fusion

Study on human growth hormone for ACL tear recovery receives funding from Mark Cuban Foundation

ACA urges NINDS to include recommendations for use of conservative forms of pain management

PanCuRx initiative to reduce pancreatic cancer fatality rate receives $4.6 million investment from OICR

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News